Literature DB >> 24272596

Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences.

Philipp Ubl1, Tatiana Gincu, Mohammad Keilani, Lothar Ponhold, Richard Crevenna, Bruno Niederle, Marcus Hacker, Shuren Li.   

Abstract

The aim of this study was to compare the side effects of the pentagastrin test and the calcium stimulation test in patients with increased basal calcitonin concentration, especially the gender-specific differences of side effects. A total of 256 patients (123 females and 133 males, mean age of 56 ± 27 years, range 21-83 years) had both pentagastrin and calcium stimulation tests. All patients filled in a questionnaire regarding the side effects within 30 min after completion of the stimulation tests. The differences of side effects between female and male patients as well as between the pentagastrin stimulation test and the calcium stimulation test were evaluated. Warmth feeling was the most frequent occurring side effect in all patients who had both pentagastrin and calcium stimulation tests, followed by nausea, altered gustatory sensation, and dizziness. The incidences of urgency to micturate (p < 0.05) and dizziness (p < 0.05) were significantly increased in the female patients as compared to male patients by calcium stimulation test. Significant higher incidences of urgency to micturate (p < 0.05) and warmth feeling (p < 0.05) were found by calcium stimulation test as compared with those by pentagastrin test in female patients. The incidences of nausea (p < 0.05) and abdominal cramping (p < 0.05) in male patients were significantly higher by pentagastrin stimulation test than by calcium stimulation test. There is a significant gender-specific difference in side effects induced by calcium stimulation test. Female patients have fewer side effects by pentagastrin test than by calcium stimulation test. Male patients may tolerate the calcium stimulation test better than the pentagastrin test.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24272596     DOI: 10.1007/s12020-013-0109-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  18 in total

1.  Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.

Authors:  Zubair Baloch; Pierre Carayon; Bernard Conte-Devolx; Laurence M Demers; Ulla Feldt-Rasmussen; Jean-François Henry; Virginia A LiVosli; Patricia Niccoli-Sire; Rhys John; Jean Ruf; Peter P A Smyth; Carole A Spencer; Jan R Stockigt
Journal:  Thyroid       Date:  2003-01       Impact factor: 6.568

2.  Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.

Authors:  Georgios Karanikas; Abbas Moameni; Christian Poetzi; Georg Zettinig; Klaus Kaserer; Christian Bieglmayer; Bruno Niederle; Robert Dudczak; Christian Pirich
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Increased calcitonin level in thyroid nodules without medullary carcinoma.

Authors:  H Gibelin; D Essique; C Jones; P Levillain; R Maréchaud; J-L Kraimps
Journal:  Br J Surg       Date:  2005-05       Impact factor: 6.939

4.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

Review 5.  Calcium stimulated calcitonin measurement: a procedural proposal.

Authors:  F A Verburg; C Reiners; I Grelle; H Barth; M Fassnacht; M Luster
Journal:  Exp Clin Endocrinol Diabetes       Date:  2013-02-21       Impact factor: 2.949

6.  Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications.

Authors:  Isabella Merante Boschin; Francesca Torresan; Antonio Toniato; Mariangela Zane; Eric Casal Ide; Gianmaria Pennelli; Lucia Rampin; Patrick M Colletti; Domenico Rubello; Maria Rosa Pelizzo
Journal:  Endocrine       Date:  2013-07-25       Impact factor: 3.633

7.  Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.

Authors:  H Vierhapper; B Niederle; C Bieglmayer; K Kaserer; S Baumgartner-Parzer
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

8.  Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion.

Authors:  M Freichel; A Zink-Lorenz; A Holloschi; M Hafner; V Flockerzi; F Raue
Journal:  Endocrinology       Date:  1996-09       Impact factor: 4.736

9.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.

Authors:  Carla Colombo; Uberta Verga; Caterina Mian; Stefano Ferrero; Michela Perrino; Leonardo Vicentini; Davide Dazzi; Giuseppe Opocher; Maria Rosa Pelizzo; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

10.  Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants.

Authors:  L Ceglia; S S Harris; H M Rasmussen; B Dawson-Hughes
Journal:  Osteoporos Int       Date:  2008-06-07       Impact factor: 4.507

View more
  5 in total

1.  [99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography.

Authors:  Aikaterini Kaloudi; Panagiotis Kanellopoulos; Thorsten Radolf; Oleg G Chepurny; Maritina Rouchota; George Loudos; Fritz Andreae; George G Holz; Berthold Artur Nock; Theodosia Maina
Journal:  Mol Pharm       Date:  2020-07-07       Impact factor: 4.939

Review 2.  [Update of the S2k guidelines : Surgical treatment of benign thyroid diseases].

Authors:  T J Musholt; A Bockisch; T Clerici; C Dotzenrath; H Dralle; P E Goretzki; M Hermann; K Holzer; W Karges; H Krude; J Kussmann; K Lorenz; M Luster; B Niederle; C Nies; P Riss; J Schabram; P Schabram; K W Schmid; D Simon; Ch Spitzweg; Th Steinmüller; A Trupka; C Vorländer; T Weber; D K Bartsch
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

3.  Safety of calcitonin stimulation tests with calcium.

Authors:  Mara Băetu; Cristina Alexandra Olariu; Ileana Nițu; Gabriel Moldoveanu; Cristina Corneci; Corin Badiu
Journal:  Hormones (Athens)       Date:  2021-09-01       Impact factor: 2.885

4.  Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test".

Authors:  Martin B Niederle; Christian Scheuba; Alois Gessl; Shuren Li; Oskar Koperek; Christian Bieglmayer; Philipp Riss; Andreas Selberherr; Bruno Niederle
Journal:  Biochem Med (Zagreb)       Date:  2018-10-15       Impact factor: 2.313

5.  Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study.

Authors:  Berthold A Nock; Panagiotis Kanellopoulos; Oleg G Chepurny; Maritina Rouchota; George Loudos; George G Holz; Eric P Krenning; Theodosia Maina
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.